Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.31%. On the other hand, the Dow registered a gain of 0.67%, and the technology-centric Nasdaq decreased by 1.09%.The the stock of pharmaceutical company has risen by 0.95% in the past month, leading the Medical sector's gain of 0.61% and undershooting the S&P 500's gain of 2.73%.Market participants will be closely following the fin ...

Loading...Loading...Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these catalysts and which way they will likely pan out. Benzinga brings to investors a weekly feature focusing on five key catalysts that could impact the stock prices of the respective companies in an appreciable manner.1. Arrowhead Pharmaceuticals, Inc. ARWRDate: Tuesday, June 25Catalyst: Discu ...

Company Performance - Merck (MRK) closed at $127.99, reflecting a +0.38% change from the previous day, outperforming the S&P 500 which gained 0.25% [1] - Over the past month, Merck's shares have decreased by 2.66%, while the Medical sector gained 0.11% and the S&P 500 increased by 3.34% [1] - The upcoming earnings report is scheduled for July 30, 2024, with expected EPS of $2.14, representing a 203.88% increase from the prior-year quarter, and revenue projected at $15.88 billion, up 5.65% from the prior-year quarter [1] Earnings Estimates - For the full year, earnings are projected at $8.62 per share and revenue at $64.4 billion, showing increases of +470.86% and +7.13% respectively from the previous year [2] - Recent changes to analyst estimates indicate positive sentiment regarding Merck's business and profitability, with estimate alterations linked to stock price performance [2] Valuation Metrics - Merck currently has a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 14.79, which is a premium compared to the industry average of 14.43 [3] - The PEG ratio for Merck stands at 2.46, compared to the Large Cap Pharmaceuticals industry's average PEG ratio of 1.78 [3] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and holds a Zacks Industry Rank of 156, placing it within the bottom 39% of over 250 industries [4] - The Zacks Industry Rank measures the strength of industry groups, indicating that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

The U.S. Food and Drug Administration (FDA) approved Merck & Co Inc's (NYSE:MRK) next-generation vaccine to protect adults against the pneumococcal disease. The company said the vaccine could become available later this summer, pending recommendation from the Centers for Disease Control and Prevention (CDC). In response, MRK is up 0.3% to trade at $127.90 at last check.Over the last few months, the security has repeatedly attempted to conquer its March 27, record high of $133.08, but the $130 level keeps ac ...

Merck (MRK) announced that the FDA had granted approval to V116, its 21-valent pneumococcal conjugate vaccine (PCV), for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. For the prevention of pneumonia indication, the FDA granted accelerated approval.The vaccine will be marketed by the trade name of Capvaxive. Capvaxive becomes the first PCV specifically designed for adults to be approved by the FDA. Capvaxive targets serotypes that account for approximately 84% of all i ...

The Food and Drug Administration on Monday approved Merck's new vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and a lung infection called pneumonia, a spokesperson for the drugmaker said.Merck's shot, called Capvaxive, specifically protects against 21 strains of that bacteria to prevent a severe form of pneumococcal disease that can spread to other parts of the body and lead to pneumonia. It's the first pneumococcal conjugate vaccine designed speci ...

Merck & Co., Inc. (NYSE:MRK) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:00 AM ET Company Participants Robert Davis - Chairman, President and Chief Executive Officer Dean Li - Executive Vice President and President, Merck Research Laboratories Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway. Good morning, everybody, and welcome to the Second Day of the conference. My name is Chris Shibutani. And on behalf of the entire Go ...

Merck & Co., Inc. (NYSE:MRK) Goldman Sachs 45th Annual Global Healthcare Conference Call June 11, 2024 10:00 AM ET Company Participants Robert Davis - Chairman, President and Chief Executive Officer Dean Li - Executive Vice President and President, Merck Research Laboratories Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay, let's get underway. Good morning, everybody, and welcome to the Second Day of the conference. My name is Chris Shibutani. And on behalf of the entire Go ...

Nudphon PhuengsuwanIntroduction I usually spend my mornings browsing various news outlets. This was part of a prior job where I provided daily macro and geopolitical newsletters for both private and institutional clients. This includes American, German, French, Italian, and newspapers from other regions. I use translation for most of these (except English, Dutch, and German languages). I mainly do this to get a good overview of what is happening across the world and how this could impact the stocks that ...

Group 1: Pfizer - Pfizer's stock has underperformed recently despite its significant contributions to COVID-19 vaccines and treatments [2] - Billionaires such as John Overdeck and Ken Griffin have increased their holdings in Pfizer, with Two Sigma Investments adding 10.5 million shares and Citadel Advisors acquiring nearly 880,000 shares [2] - Pfizer's revenue and net income have declined as the COVID-19 related boost has diminished, but the company is expanding its product pipeline significantly [3] - The company has received seven new product approvals in the past year, indicating a rejuvenated pipeline that is expected to yield more than the previous one or two approvals per year [3] - Pfizer's acquisition of Seagen for $43 billion has enhanced its oncology capabilities, and it has consistently raised its dividends by 61.5% over the past decade, with a forward yield of 5.86% [4] Group 2: Merck - Merck has also attracted billionaire investors, with Citadel Advisors purchasing 1.26 million shares and Millennium Management acquiring 4.02 million shares [5] - Keytruda, Merck's leading cancer therapy, generated $6.9 billion in revenue, accounting for nearly 44% of total sales, which increased by 9% year over year to $15.8 billion [5][6] - Merck is developing a subcutaneous formulation of Keytruda to extend its market presence as the patent exclusivity will expire by 2028 [6] - The company has received a new approval for Winrevair, a treatment for pulmonary arterial hypertension, with peak sales projected to exceed $2 billion [7] - Merck has raised its dividends by 75% over the past decade, with a forward yield of over 2.45%, making it an attractive option for income-seeking investors [7]